Gilead Signs US$1.53 B Deal with Scholar Rock to Strengthen its Fibrotic Diseases Pipeline

By Sharath Chandra Nakka & Michelle Liu

Pharma Deals Review: Vol 2019 Issue 1 (Table of Contents)

Published: 8 Jan-2019

DOI: 10.3833/pdr.v2019.i1.2391     ISSN: 1756-7874

Section: Research & Development



With a focus on strengthening its fibrotic diseases pipeline, Gilead has agreed to collaborate with Scholar Rock to gain exclusive developmental and commercialisation rights to its transforming growth factor beta programme candidates for the treatment of fibrotic diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details